These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 15741556)

  • 1. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
    Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
    Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.
    Monath TP; Nichols R; Archambault WT; Moore L; Marchesani R; Tian J; Shope RE; Thomas N; Schrader R; Furby D; Bedford P
    Am J Trop Med Hyg; 2002 May; 66(5):533-41. PubMed ID: 12201587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial.
    Pfister M; Kürsteiner O; Hilfiker H; Favre D; Durrer P; Ennaji A; L'Age-Stehr J; Kaufhold A; Herzog C
    Am J Trop Med Hyg; 2005 Mar; 72(3):339-46. PubMed ID: 15772332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
    Collaborative Group for Studies with Yellow Fever Vaccine
    Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
    Monath TP; Lee CK; Julander JG; Brown A; Beasley DW; Watts DM; Hayman E; Guertin P; Makowiecki J; Crowell J; Levesque P; Bowick GC; Morin M; Fowler E; Trent DW
    Vaccine; 2010 May; 28(22):3827-40. PubMed ID: 20347059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
    Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines.
    Lang J; Zuckerman J; Clarke P; Barrett P; Kirkpatrick C; Blondeau C
    Am J Trop Med Hyg; 1999 Jun; 60(6):1045-50. PubMed ID: 10403341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
    Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
    Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of the yellow Fever vaccine: a retrospective study.
    Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
    J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
    Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
    J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological Protection 5-6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes.
    Idoko OT; Domingo C; Tapia MD; Sow SO; Geldmacher C; Saathoff E; Kampmann B
    Front Immunol; 2020; 11():577751. PubMed ID: 33133096
    [No Abstract]   [Full Text] [Related]  

  • 13. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.
    Gaspar LP; Mendes YS; Yamamura AM; Almeida LF; Caride E; Gonçalves RB; Silva JL; Oliveira AC; Galler R; Freire MS
    J Virol Methods; 2008 Jun; 150(1-2):57-62. PubMed ID: 18420285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next generation yellow fever vaccine induces an equivalent immune and transcriptomic profile to the current vaccine: observations from a phase I randomised clinical trial.
    Pagnon A; Carre C; Aguirre M; Chautard E; Gimenez S; Raynal F; Feroldi E; Scott P; Modjarrad K; Vangelisti M; Mantel N
    EBioMedicine; 2024 Oct; 108():105332. PubMed ID: 39293214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
    Barrett AD; Teuwen DE
    Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study.
    Kernéis S; Launay O; Ancelle T; Iordache L; Naneix-Laroche V; Méchaï F; Fehr T; Leroy JP; Issartel B; Dunand J; van der Vliet D; Wyplosz B; Consigny PH; Hanslik T
    Arthritis Care Res (Hoboken); 2013 Sep; 65(9):1522-8. PubMed ID: 23554297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.
    Poland JD; Calisher CH; Monath TP; Downs WG; Murphy K
    Bull World Health Organ; 1981; 59(6):895-900. PubMed ID: 6978196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.
    Kitchener S
    Vaccine; 2004 Jun; 22(17-18):2103-5. PubMed ID: 15149765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
    Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N
    Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.